TriStar Wellness Solutions, Inc., a health and wellness company that targets opportunities in the self-care and professional marketplace, announced that HemCon Medical Technologies, a wholly owned subsidiary of TWSI, has launched a global initiative to target the hemodialysis market with a new product from the chitosan line of hemostatic and antibacterial barrier devices family.
With 2.1 million patients undergoing dialysis globally on a yearly basis and 8% of the population having great difficulty achieving hemostasis after the procedure, the dialysis market is valued at $27 million for problem bleeders alone, and over $370 million for the overall population1. The leading countries driving growth in the market are the US, Japan, and the European Union. Leveraging strong existing relationships in these territories, HemCon plans to release an innovative product in Q2-2014, in the meantime we are working with our partners to collect valuable clinical data to provide HemCon a strategic advantage within this market.
With the feedback from these partners we have created a dressing that fulfills all the requirements of this specific application. Dialysis patients undergo treatment three times a week and their body's natural mechanism of forming a clot to stop bleeding is compromised, causing the dialysis access sites to suffer from nuisance bleeding. Dialysis wounds are also prone to irritation and infection.
Status quo treatment does not fulfill all the requirements for ideal patient care. The HemCon dialysis dressing provides superior bleeding control for these compromised patients thanks to chitosan's hemostatic properties, as well as an antibacterial barrier against at least 24 microorganisms. Catheter-related infections in hemodialysis are one of the most common causes of morbidity and mortality in patients with end-stage renal disease. Staphylococcus aureus is the most common causative organism isolated2, and the HemCon dialysis dressing provides an efficacious barrier against this organism as many other gram positive and negative strains.
"With our superior hemostatic properties and working as a barrier to organisms that cause infection, HemCon will strive to become a leader in hemodialysis care across the world," said Bill Shields, Sr. Vice President of Sales and Business Development for HemCon. "We look forward to targeting this key market and expanding HemCon's global reach."